Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
      • Partners
  • Technology
      • Advantages of Emergex’s Vaccines
      • T-Cell Adaptive Vaccine
      • Pipeline
  • Media Centre
    • In the News
    • Press Releases
  • Careers
      • Technical Support Position
  • Contact Us
  • Menu Menu
You are here: Home1 / Technology2 / T-cell Adaptive Vaccines

We have developed the first approach to making T-Cell Priming Vaccines using experimentally-selected purely synthetic non-biological components that programme immune cells to destroy pathogen-producing cells.

These vaccines ‘prime’ the immune systems of recipients to recognise subsequent infectious agents much like a natural infection would do, and thus preventing an acute or severe manifestation of the disease.

Learn more about the advantages of our technology

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top